This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brasch, H. Articles by Dominiak, P. Search for Related Content PubMed PubMed Citation Articles by Brasch, H. Articles by Dominiak, P.

Hypertension, Vol 22, 699-704, Copyright © 1993 by American Heart Association

ARTICLES

Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors

H Brasch, L Sieroslawski and P Dominiak
Institute of Pharmacology, Medical University of Lubeck, FRG.

Norepinephrine stores in electrically driven guinea pig isolated atria were loaded with [3H]norepinephrine, and norepinephrine release was deduced from the radioactivity efflux. Electrical field stimulation of sympathetic nerve endings was applied during the refractory period of atrial contractions. The stimulation-induced release of norepinephrine was increased by angiotensin II (Ang II) (10(-8) to 10(-6) mol/L) in a concentration-dependent manner. The maximum observed effect was a 55% augmentation. The effects of 10(-7) and 10(-6) mol/L Ang II were abolished by 10(-6) and 10(-5) mol/L of the subtype 1 Ang II receptor antagonist losartan, respectively. Losartan by itself (10(-6) mol/L) caused a 14% reduction of norepinephrine release. The subtype 2 Ang II receptor ligand PD 123319 (1-[[4-(dimethylamino)-3-methylphenyl]methyl]- 5-(diphenylacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6- carboxylic acid ditrifluoroacetate) in a concentration of 10(-4) mol/L had no detectable influence on transmitter release and did not antagonize the effect of Ang II. Angiotensin I (10(-6) and 10(-5) mol/L) increased norepinephrine release maximally by 23%. This effect was antagonized by 10(-5) mol/L losartan and did not appear in the presence of 10(-6) mol/L of the converting enzyme inhibitor ramiprilat. These results suggest that Ang II increases norepinephrine release by an activation of subtype 1 receptors, whereas angiotensin I is converted to Ang II to become effective.

This article has been cited by other articles:

				M. Byku, H. Macarthur, and T. C. Westfall Nerve stimulation induced overflow of neuropeptide Y and modulation by angiotensin II in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2188 - H2197. [Abstract] [Full Text] [PDF]

				N. Guler, C. Ozkara, H. Dulger, V. Kutay, M. Sahin, E. Erbilen, and H. A. Gumrukcuoglu Do Cardiac Neuropeptides Play a Role in the Occurrence of Atrial Fibrillation After Coronary Bypass Surgery? Ann. Thorac. Surg., February 1, 2007; 83(2): 532 - 537. [Abstract] [Full Text] [PDF]

				M. Nishikino, T. Matsunaga, K. Yasuda, T. Adachi, T. Moritani, G. Tsujimoto, K. Tsuda, and N. Aoki Genetic Variation in the Renin-Angiotensin System and Autonomic Nervous System Function in Young Healthy Japanese Subjects J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4676 - 4681. [Abstract] [Full Text] [PDF]

				A. El-Armouche, P. Boknik, T. Eschenhagen, L. Carrier, M. Knaut, U. Ravens, and D. Dobrev Molecular Determinants of Altered Ca2+ Handling in Human Chronic Atrial Fibrillation Circulation, August 15, 2006; 114(7): 670 - 680. [Abstract] [Full Text] [PDF]

				Y. Yin, D. Dalal, Z. Liu, J. Wu, D. Liu, X. Lan, Y. Dai, L. Su, Z. Ling, Q. She, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation Eur. Heart J., August 1, 2006; 27(15): 1841 - 1846. [Abstract] [Full Text] [PDF]

				M. El Muayed Reduced atrial fibrillation incidence by angiotensin-converting enzyme inhibitors: A possible contributing mechanism J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1144 - 1144. [Full Text] [PDF]

				T. Ohta, N. Hasebe, S. Tsuji, K. Izawa, Y.-T. Jin, S. Kido, S. Natori, M. Sato, and K. Kikuchi Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2914 - H2921. [Abstract] [Full Text] [PDF]

				W. Raasch, P. Dominiak, A. Ziegler, and A. Dendorfer Reduction of Vascular Noradrenaline Sensitivity by AT1 Antagonists Depends on Functional Sympathetic Innervation Hypertension, September 1, 2004; 44(3): 346 - 351. [Abstract] [Full Text] [PDF]

				O. Johren, A. Dendorfer, and P. Dominiak Cardiovascular and renal function of angiotensin II type-2 receptors Cardiovasc Res, June 1, 2004; 62(3): 460 - 467. [Abstract] [Full Text] [PDF]

				J. Tallaj, C.-C. Wei, G. H. Hankes, M. Holland, P. Rynders, A. R. Dillon, J. L. Ardell, J. A. Armour, P. A. Lucchesi, and L. J. Dell'Italia {beta}1-Adrenergic Receptor Blockade Attenuates Angiotensin II-Mediated Catecholamine Release Into the Cardiac Interstitium in Mitral Regurgitation Circulation, July 15, 2003; 108(2): 225 - 230. [Abstract] [Full Text] [PDF]

				A. Nap, J. C Balt, M. Pfaffendorf, and P. A van Zwieten No involvement of the AT2-receptor in angiotensin II-enhanced sympathetic transmission in vitro Journal of Renin-Angiotensin-Aldosterone System, June 1, 2003; 4(2): 100 - 105. [Abstract] [PDF]

				O. Johren, C. Golsch, A. Dendorfer, F. Qadri, W. Hauser, and P. Dominiak Differential Expression of AT1 Receptors in the Pituitary and Adrenal Gland of SHR and WKY Hypertension, April 1, 2003; 41(4): 984 - 990. [Abstract] [Full Text] [PDF]

				T. W. Lameris, S. de Zeeuw, D. J. Duncker, G. Alberts, F. Boomsma, P. D. Verdouw, and A. H. van den Meiracker Exogenous Angiotensin II Does Not Facilitate Norepinephrine Release in the Heart Hypertension, October 1, 2002; 40(4): 491 - 497. [Abstract] [Full Text] [PDF]

				J. C Balt, M.-J. Mathy, A. Nap, M. Pfaffendorf, and P. A van Zwieten Involvement of the AT2-receptor in angiotensin II-induced facilitation of sympathetic neurotransmission Journal of Renin-Angiotensin-Aldosterone System, September 1, 2002; 3(3): 181 - 187. [Abstract] [PDF]

				A. Dendorfer, A. Thornagel, W. Raasch, O. Grisk, K. Tempel, and P. Dominiak Angiotensin II Induces Catecholamine Release by Direct Ganglionic Excitation Hypertension, September 1, 2002; 40(3): 348 - 354. [Abstract] [Full Text] [PDF]

				W. Raasch, T. Bartels, A. Gieselberg, A. Dendorfer, and P. Dominiak Angiotensin I-Converting Enzyme Inhibition Increases Cardiac Catecholamine Content and Reduces Monoamine Oxidase Activity via an Angiotensin Type 1 Receptor-Mediated Mechanism J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 428 - 434. [Abstract] [Full Text] [PDF]

				D. M. Farrell, C.-C. Wei, J. Tallaj, J. L. Ardell, J. A. Armour, G. R. Hageman, W. E. Bradley, and L. J. Dell'Italia Angiotensin II modulates catecholamine release into interstitial fluid of canine myocardium in vivo Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H813 - H822. [Abstract] [Full Text] [PDF]

				S. S. Shetty and D. DelGrande Differential Inhibition of the Prejunctional Actions of Angiotensin II in Rat Atria by Valsartan, Irbesartan, Eprosartan, and Losartan J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 179 - 186. [Abstract] [Full Text]

				S. MYOU, M. FUJIMURA, Y. KAMIO, Y. ISHIURA, K. KURASHIMA, H. TACHIBANA, T. HIROSE, and T. HASHIMOTO Effect of Losartan, a Type 1 Angiotensin II Receptor Antagonist, on Bronchial Hyperresponsiveness to Methacholine in Patients with Bronchial Asthma Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 40 - 44. [Abstract] [Full Text]

				M. J. Clair, M. K. King, A. T. Goldberg, J. W. Hendrick, R. Nisato, D. M. Gay, A. E. Morrison, J. H. McElmurray III, R. S. Krombach, B. R. Bond, et al. Selective Vasopressin, Angiotensin II, or Dual Receptor Blockade with Developing Congestive Heart Failure J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 852 - 860. [Abstract] [Full Text]

				H. P. Brunner-La Rocca, G. Vaddadi, and M. D. Esler Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1163 - 1173. [Abstract] [Full Text] [PDF]

				N. Seyedi, T. Win, H. M. Lander, and R. Levi Bradykinin B2-Receptor Activation Augments Norepinephrine Exocytosis From Cardiac Sympathetic Nerve Endings : Mediation by Autocrine/Paracrine Mechanisms Circ. Res., November 19, 1997; 81(5): 774 - 784. [Abstract] [Full Text]